Stability of rare TP53 co-mutations in AML patients.

被引：0
|
作者：
Bloom, Kenneth Joel
Idica, Adam
Smart, Dave
Allen, Wendy
Scanlon, Enya
Clark, Jordan
机构：
[1] Clarient Diagnost Serv Inc, Aliso Viejo, CA USA
[2] DIACEUTICS, Carlsbad, CA USA
[3] Diaceutics, Belfast, Antrim, North Ireland
[4] Queens Univ Belfast, Belfast, Antrim, North Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7528
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
    A Langerød
    TI Andersen
    I Bukholm
    A-L Børresen Dale
    Breast Cancer Research, 2 (Suppl 1)
  • [22] Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma
    Liu, Di-Han
    Zhao, Ze-Rui
    Lin, Yao-Bin
    Zhou, Wen-Jie
    Hou, Jing-Yu
    Ye, Zheng-Hao
    Long, Hao
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (06) : 1934 - 1941
  • [23] Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma
    Di-Han Liu
    Ze-Rui Zhao
    Yao-Bin Lin
    Wen-Jie Zhou
    Jing-Yu Hou
    Zheng-Hao Ye
    Hao Long
    Annals of Surgical Oncology, 2019, 26 : 1934 - 1941
  • [24] KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
    Gu, Meichen
    Xu, Tiankai
    Chang, Pengyu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [25] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    A Stengel
    W Kern
    T Haferlach
    M Meggendorfer
    A Fasan
    C Haferlach
    Leukemia, 2017, 31 : 705 - 711
  • [26] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    Stengel, A.
    Kern, W.
    Haferlach, T.
    Meggendorfer, M.
    Fasan, A.
    Haferlach, C.
    LEUKEMIA, 2017, 31 (03) : 705 - 711
  • [27] IMPACT OF ALLELIC STATUS OF TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML)
    Ibanez, Mariam
    Barragan, Eva
    Roson-Burgo, Beatriz
    Such, Esperanza
    Avetisya, Gayane
    Mora, Elvira
    Liquori, Alessandro
    Sargas, Claudia
    Llop, Marta
    Senent, Leonor
    Vicente, Ana
    Luna, Irene
    Sempere, Amparo
    Andreu, Rafa
    Montesinos, Pau
    Cervera, Jose
    Sanz, Guillermo
    HAEMATOLOGICA, 2020, 105 : 5 - 6
  • [28] The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML
    Wong, Terrence Neal
    Ramsingh, Giridharan
    Young, Andrew
    Shen, Dong
    Miller, Chris
    Lamprecht, Tamara
    Heath, Sharon
    Fulton, Robert S.
    Mardis, Elaine R.
    Ding, Li
    Westervelt, Peter
    Welch, John
    Walter, Matthew J.
    Graubert, Timothy
    DiPersio, John F.
    Ley, Timothy J.
    Druley, Todd E.
    Wilson, Richard K.
    Link, Daniel C.
    BLOOD, 2013, 122 (21)
  • [29] Essential thrombocytosis transformed AML with TP53 mutations and its clinical implications
    Yang Si
    Jiyuan Wang
    Brett D Hambly
    Yuli Wang
    Yanfang Zhang
    Shisan Bao
    Discover Oncology, 15 (1)
  • [30] TP53 mutations in Romanian patients with colorectal cancer
    Felix Manirakiza
    Hidetaka Yamada
    Yuji Iwashita
    Keiko Ishino
    Rei Ishikawa
    Zsolt Kovacs
    Eva Osvath
    Augustin Nzitakera
    Simona Gurzu
    Haruhiko Sugimura
    Genes and Environment, 45
12345